Table 1.
Baseline characteristics (N = 546)
| Age (years) | 33 ± 9 |
|---|---|
| Male | 334 (61%) |
| Body mass index (kg/m2) | 26 ± 4 |
| Body surface area (m2) | 1.9 ± 0.3 |
| Hypertension diagnosis | 326 (60%) |
| Bicuspid aortic valve | 309 (57%) |
| NYHA II–IV | 214 (39%) |
| Medications | |
| Beta blockers | 142 (26%) |
| Calcium channel blockers | 59 (11%) |
| ACEI/ARB | 129 (24%) |
| Thiazide | 47 (9%) |
| Hydralazine | 3 (0.5%) |
| Any BP medication | 341 (62%) |
| Echocardiography | |
| LV end-diastolic dimension (mm) | 49 ± 6 |
| LV end-systolic dimension (mm) | 30 ± 5 |
| LV ejection fraction (%) | 62 ± 7 |
| LV septal wall thickness (mm) | 9 ± 2 |
| LV posterior wall thickness (mm) | 10 ± 2 |
| Aortic valve peak velocity (m/s) | 1.4 ± 0.3 |
| COA peak velocitya (m/s) | 2.7 ± 0.5 |
| Cross-sectional imaging data | |
| Mid ascending aorta (mm) | 30 ± 7 |
| Distal ascending aorta (mm) | 25 ± 6 |
| Proximal aortic arch (mm) | 19 ± 7 |
| Distal aortic arch (mm) | 19 ± 8 |
| Aortic isthmus (mm) | 14 ± 5 |
| Proximal descending aorta (mm) | 22 ± 7 |
| Descending aorta at diaphragm (mm) | 20 ± 5 |
Data were presented as mean ± standard deviation or number (%).
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; COA, coarctation of aorta; LV, left ventricle; LVMI, left ventricular mass index; SBP, systolic blood pressure; ULE, upper-to-lower extremity.
a
COA peak gradient represents uncorrected maximum instantaneous gradient.